Dark blue gradeint overlay Aro line two

CREATING A NEW CLASS OF RECEPTOR TARGETED GENETIC MEDICINES

Selective modulation of gene targets in the disease tissue to achieve superior efficacy and safety

Dark%20blue%20gradeint%20overlay_edited.
Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

 

ABOUT US

Aro is a product-focused platform company, developing a wholly owned proprietary pipeline and a partnered pipeline of Centyrin-RNA drug conjugates to address previously intractable diseases.

 

OUR SCIENCE

We discover and optimize receptor-specific Centyrins and conjugate them to oligonucleotides to precisely modulate gene targets in disease tissues.

JOIN US

If you are interested in working on the cutting edge of genetic medicine and making a meaningful difference in patients' lives, come join our team!

 

Centyrin-White Icon.png

LATEST NEWS

LATEST NEWS

February 24, 2021


Aro Biotherapeutics Expands Leadership Team with Addition of Proven Scientific Executives

January 5, 2021

Aro Biotherapeutics Announces $88 Million Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines

October 13, 2020

Aro Biotherapeutics Appoints Biotechnology Executive Dr. Christopher Mirabelli to its Board of Directors and Nucleic Acid Therapeutics Expert Dr. Masad Damha to its Scientific Advisory Board